

## SYNTHESIS AND PROPERTIES OF 4-(3-AMINOTHIENO-[2,3-*b*]PYRIDIN-2-YL)COUMARINS

S. V. Gorelov<sup>1</sup>, S. P. Bondarenko<sup>2</sup>, and M. S. Frasinyuk<sup>3\*</sup>

*Substituted 4-[(3-cyanopyridin-2-yl)thiomethyl]coumarins have been synthesized by the alkylation of 2-mercaptop-4,6-dimethylnicotinonitrile with 4-chloromethylcoumarins. Substituted 4-(3-aminothieno[2,3-*b*]pyridin-2-yl)coumarins have been obtained by a subsequent intramolecular condensation of the methylene and cyano groups. 6H-Chromeno[4,3-*d*]thieno[3,2-*b*:5,4-*b*']dipyridin-6-ones were isolated as a result of the interaction of these compounds with aldehydes, and their aminomethyl derivatives were synthesized.*

**Keywords:** 4-chloromethylcoumarin, 5*H*-chromeno[3,4-*c*]pyridin-5-one, 6*H*-chromeno[4,3-*d*]thieno[3,2-*b*:5,4-*b*']dipyridin-6-one, 1,2-dihydropyridine, 4-(thieno[2,3-*b*]pyridin-2-yl)coumarin, aminomethylation.

Natural 4-arylcoumarins (neoflavones) [1-3], as also their synthetic analogs, 4-hetarylcoumarins, display various types of biological activity [4, 5]. In particular, recent investigations of the biological properties of 4-pyridylcoumarins revealed among them compounds with high anticancer [6], anti-inflammatory, analgesic, and antimicrobial [7] activity. In view of these circumstances, the search for synthetic routes towards new pyridine-containing coumarins seemed of interest.

In addition to the main methods of 4-arylcoumarin synthesis [8], the cross-coupling of 4-trifluoromethanesulfonyloxycoumarins and 4-tosyloxycoumarins with (het)arylboronic acids or their pinacol esters [4, 5, 9], and also with hetaryl organometallic compounds [10, 11], is increasingly used at the present time.

4-Chloromethylcoumarin derivatives are convenient intermediates for introduction of a hetaryl substituent into the position 4 of the coumarin system. Recently, using 4-chloromethylcoumarins and the (7-hydroxy-2-oxo-2*H*-chromen-4-yl)acetic acid methyl ester, we improved the synthesis of 4-(2-benzofuryl)coumarins [12] and 4-(2-oxo-2*H*-chromen-3-yl)coumarins [13], respectively.

In the present study, we have used 4-chloromethylcoumarins for the synthesis of 4-(thieno[2,3-*b*]pyridin-2-yl)coumarin derivatives by the alkylation of 2-mercaptop-4,6-dimethylnicotinonitrile (see [6]).


\*To whom correspondence should be addressed, e-mail: horelovs@ukr.net.

<sup>1</sup>PJSC SIC "Borshchahivskiy Chemical Pharmaceutical Plant", 17 Mira St., Kyiv 03134, Ukraine.

<sup>2</sup>National University of Food Technology, 68 Volodyimirskaya St., Kyiv 01601, Ukraine; e-mail: sp\_bondarenko@ukrpost.ua.

<sup>3</sup>Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine, 1 Murmanska St., Kyiv 02094, Ukraine; e-mail: mfras@i.kiev.ua.

Translated from *Khimiya Geterotsiklicheskikh Soedinenii*, No. 6, pp. 1026-1033, June, 2012. Original article submitted August 18, 2011.



Choice of the latter enabled the use of 4-chloromethylcoumarins containing phenolic hydroxyl groups as alkylating agents, since the significant difference in nucleophilicity of the mercapto group and phenolic hydroxyl directed the course of the reaction exclusively to the sulfur atom.

We found that the 4-chloromethylcoumarins **1a-h** interact with 2-mercaptopurine at room temperature with the formation of 4-(2-pyridylthiomethyl)coumarins **2a-h** (Tables 1, 2).

The intramolecular cyclization of the methylene and cyano groups in 4-(2-pyridylthiomethyl)coumarins **2a-h** was carried out in DMF under the action of potassium carbonate that led to the formation of substituted 4-(3-aminothieno[2,3-*b*]pyridin-2-yl)coumarins **3a-h**. The synthesized compounds **3a-h** were high-melting yellow substances, sparingly soluble in organic solvents and readily soluble in aqueous solutions of mineral acids and alkali.

The presence of amino groups in compounds **3a-h** was demonstrated by <sup>1</sup>H NMR spectroscopy. For instance, a two-proton broadened singlet was observed in the 5.08–5.24 ppm region of the <sup>1</sup>H NMR spectra of the synthesized substituted coumarins **3a-h**, which corresponds to the amino group (Table 2).


One of the interesting routes for modification of the amino group, in our view, is the construction of a pyrrole ring with the aid of 2,5-dimethoxytetrahydrofuran. We found that brief heating of amines **3b,d,f,g** with this reagent in acetic acid led to the formation of 1-(thieno[2,3-*b*]pyridin-3-yl)pyrroles **4a-d**.

It was shown previously in [7, 12], that 4-(3-aminobenzofuran-2-yl)coumarins are convenient starting materials for the construction of the pyrido[3,4-*c*]coumarin system, which is a structural fragment of alkaloids isolated from *Schumanniphylon problematicum* [14]. At this time various methods for the synthesis of 5*H*-chromeno[3,4-*c*]pyridin-5-one derivatives have been developed (see literature review in [12]).

As it turned out, the interaction of compounds **3a,c,g,h** with aliphatic or aromatic aldehydes in formic acid with subsequent oxidation of the intermediate products **5a,b,d-f** with diacetoxyiodosobenzene enabled the preparation of derivatives **6a,b,d-f** of a new condensed system, 6*H*-chromeno[4,3-*d*]thieno[3,2-*b*:5,4-*b*']dipyridin-6-one. In the case of the synthesis of compound **6c** it proved to be expedient to use triethyl orthoformate [7]. We propose that, as in the case of derivatives of 6*H*-[1]benzofuro[3,2-*b*]chromeno[4,3-*d*]pyridin-6-ones [12], the synthesis of compounds **6a,b,d-f** proceeds through the sequential generation of a Schiff base, its intramolecular cycloaddition with the formation of condensed 1,2-dihydropyridines **5a,b,d-f**, and oxidation of the latter to pyridine derivatives.

TABLE 1. Physicochemical Characteristics of Coumarin Derivatives **1f,g**,  
**2a-h**, **3a-h**, **4a-d**, **6a-f**, **7a-c**

Com- ound	Empirical formula	Found, %				Mp, °C	Yield, %
		C	H	N	S		
<b>1f</b>	C <sub>10</sub> H <sub>6</sub> Cl <sub>2</sub> O <sub>3</sub>	49.17 49.01	2.58 2.47			271-272	56
<b>1g</b>	C <sub>12</sub> H <sub>11</sub> ClO <sub>3</sub>	60.28 60.39	4.53 4.65			219-220	72
<b>2a</b>	C <sub>19</sub> H <sub>16</sub> N <sub>2</sub> O <sub>2</sub> S	67.65 67.84	4.86 4.79	8.47 8.33	9.41 9.53	220-221	80
<b>2b</b>	C <sub>21</sub> H <sub>18</sub> N <sub>2</sub> O <sub>2</sub> S	69.67 69.59	5.12 5.01	7.81 7.73	8.93 8.85	248-250	77
<b>2c</b>	C <sub>18</sub> H <sub>14</sub> N <sub>2</sub> O <sub>3</sub> S	63.76 63.89	3.99 4.17	8.16 8.28	9.56 9.48	265-266	81
<b>2d</b>	C <sub>19</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub> S	64.85 64.76	4.46 4.58	7.77 7.95	9.22 9.10	285-287	79
<b>2e</b>	C <sub>24</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub> S	69.47 69.55	4.25 4.38	6.85 6.76	7.82 7.74	270-271	75
<b>2f</b>	C <sub>18</sub> H <sub>13</sub> ClN <sub>2</sub> O <sub>3</sub> S	58.12 57.99	3.64 3.51	7.38 7.51	8.71 8.60	262-264	82
<b>2g</b>	C <sub>20</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub> S	65.35 65.56	5.07 4.95	7.72 7.64	8.63 8.75	241-242	75
<b>2h</b>	C <sub>19</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub> S	64.94 64.76	4.47 4.58	7.72 7.95	9.25 9.10	274-275	83
<b>3a</b>	C <sub>19</sub> H <sub>16</sub> N <sub>2</sub> O <sub>2</sub> S	67.65 67.84	4.89 4.79	8.45 8.33	9.41 9.53	208-210	76
<b>3b</b>	C <sub>21</sub> H <sub>18</sub> N <sub>2</sub> O <sub>2</sub> S	69.78 69.59	5.13 5.01	7.65 7.73	8.67 8.85	226-228	69
<b>3c</b>	C <sub>18</sub> H <sub>14</sub> N <sub>2</sub> O <sub>3</sub> S	63.99 63.89	4.28 4.17	8.41 8.28	9.39 9.48	>300	71
<b>3d</b>	C <sub>19</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub> S	64.57 64.76	4.80 4.58	8.14 7.95	9.22 9.10	>300	75
<b>3e</b>	C <sub>24</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub> S	69.38 69.55	4.49 4.38	6.87 6.76	7.67 7.74	>300	79
<b>3f</b>	C <sub>18</sub> H <sub>13</sub> ClN <sub>2</sub> O <sub>3</sub> S	58.07 57.99	3.67 3.51	7.29 7.51	8.47 8.60	186-187	76
<b>3g</b>	C <sub>20</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub> S	65.80 65.56	4.87 4.95	7.75 7.64	8.64 8.75	259-260	73
<b>3h</b>	C <sub>19</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub> S	64.59 64.76	4.80 4.58	8.14 7.95	9.02 9.10	>300	75
<b>4a</b>	C <sub>25</sub> H <sub>20</sub> N <sub>2</sub> O <sub>2</sub> S	72.92 72.79	4.75 4.89	6.91 6.79	7.85 7.77	237-239	46
<b>4b</b>	C <sub>23</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub> S	68.46 68.64	4.47 4.51	6.83 6.96	8.05 7.97	275-276	58
<b>4c</b>	C <sub>22</sub> H <sub>15</sub> ClN <sub>2</sub> O <sub>3</sub> S	62.75 62.49	3.73 3.58	6.50 6.62	7.68 7.58	274-275	57
<b>4d</b>	C <sub>24</sub> H <sub>20</sub> N <sub>2</sub> O <sub>3</sub> S	69.35 69.21	4.90 4.84	6.51 6.73	7.88 7.70	>300	62
<b>6a</b>	C <sub>30</sub> H <sub>26</sub> N <sub>2</sub> O <sub>2</sub> S	75.46 75.29	5.63 5.48	5.73 5.85	6.58 6.70	301	63
<b>6b</b>	C <sub>26</sub> H <sub>18</sub> N <sub>2</sub> O <sub>4</sub> S	68.92 68.71	3.87 3.99	6.28 6.16	6.87 7.05	>300	48
<b>6c</b>	C <sub>21</sub> H <sub>16</sub> N <sub>2</sub> O <sub>3</sub> S	66.89 67.01	4.24 4.28	7.65 7.44	8.33 8.52	>300	65
<b>6d</b>	C <sub>22</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub> S	67.81 67.67	4.59 4.65	7.37 7.17	8.44 8.21	288-290	38
<b>6e</b>	C <sub>28</sub> H <sub>22</sub> N <sub>2</sub> O <sub>4</sub> S	69.82 69.69	4.73 4.60	5.63 5.81	6.54 6.64	>300	45
<b>6f</b>	C <sub>28</sub> H <sub>22</sub> N <sub>2</sub> O <sub>5</sub> S	67.39 67.46	4.59 4.45	5.81 5.62	6.32 6.43	>300	56
<b>7a</b>	C <sub>24</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub> S	66.64 66.49	5.18 5.35	9.79 9.69	7.59 7.40	>300	76
<b>7b</b>	C <sub>26</sub> H <sub>25</sub> N <sub>3</sub> O <sub>4</sub> S	65.92 65.67	5.35 5.30	8.72 8.84	6.82 6.74	275-277	58
<b>7c</b>	C <sub>28</sub> H <sub>29</sub> N <sub>3</sub> O <sub>3</sub> S	69.14 68.97	6.11 5.99	8.50 8.62	6.68 6.58	261-262	61



The synthesized polycyclic compounds **6a-f** are high-melting crystalline substances, poorly soluble in organic solvents.

On heating compound **6c** with aminals in dioxane, aminomethylation occurs with the formation of Mannich bases **7a-c**, which are readily soluble in organic solvents and in dilute solutions of mineral acids.

Therefore, it has been shown by us that 4-(3-aminohetaryl)coumarins may be convenient starting materials for the synthesis of condensed polycyclic derivatives of 5*H*-chromeno[3,4-*c*]pyridin-5-one. Derivatives of a new heterocyclic system, 6*H*-chromeno[4,3-*d*]thieno[3,2-*b*:5,4-*b*']dipyridin-6-one, have been synthesized by the interaction of 4-(3-aminothieno[2,3-*b*]pyridin-2-yl)coumarins with aldehydes, followed by intramolecular cyclization and oxidation. Aminomethylation of these compounds under the action of aminals has been studied.

## EXPERIMENTAL

The IR spectra were recorded on a Nicolet 380 FT-IR in KBr pellets. The <sup>1</sup>H NMR spectra were recorded on a Varian VXR 300 spectrometer at 300 MHz, internal standard was TMS. Melting points were determined on a Buchi B-535 instrument. A check on the progress of reactions and the purity of the obtained compounds was carried out by TLC on Merck 60 F254 plates, the eluent was CHCl<sub>3</sub>-MeOH, 9:1, 19:1.

Compounds **1a-e,h** were synthesized by the procedures of [15-17].

**6-Chloro-4-chloromethyl-7-hydroxy-2*H*-chromen-2-one (**1f**) and 4-Chloromethyl-6-ethyl-7-hydroxy-2*H*-chromen-2-one (**1g**).** A mixture of 4-chloroacetoacetic ester (16.46 g, 0.1 mol) and the 2-substituted resorcinol (0.1 mol) was poured into 73% H<sub>2</sub>SO<sub>4</sub> (50 ml) and stirred for 18-24 h at room temperature. The reaction mixture was poured onto ice, the precipitated solid was filtered off, washed with water, and crystallized from MeOH.

TABLE 2. Spectral Characteristics of the Synthesized Compounds **1f,g**,  
**2a-h**, **3a-h**, **4a-d**, **6a-f**, **7a-c**

Com- ound	IR spectrum, $\nu$ , $\text{cm}^{-1}$	$^1\text{H}$ NMR spectrum, $\delta$ , ppm ( $J$ , Hz)*
1	2	3
<b>1f</b>	3288, 1707, 1614, 1398, 640	5.00 (2H, s, $\text{CH}_2\text{Cl}$ ); 6.49 (1H, s, H-3); 6.94 (1H, s, H-8); 7.86 (1H, s, H-5); 11.51 (1H, s, 7-OH)
<b>1g</b>	3270, 1716, 1618, 1392, 892	1.20 (3H, t, $^3J = 7.4$ , $\text{CH}_2\text{CH}_3$ ); 2.62 (2H, q, $^3J = 7.4$ , $\text{CH}_2\text{CH}_3$ ); 4.83 (2H, s, $\text{CH}_2\text{Cl}$ ); 6.29 (1H, s, H-3); 6.74 (1H, s, H-8); 7.42 (1H, s, H-5); 10.30 (1H, br. s, 7-OH)
<b>2a</b>	2216, 1716, 1621, 1575, 1543	2.39 (6H, s) and 2.49 (3H, s, 4',6'- $\text{CH}_3$ ); 4.74 (2H, s, $\text{CH}_2\text{S}$ ); 6.59 (1H, s, H-3); 7.15 (1H, s, H-5'); 7.31 (1H, d, $^3J = 8.4$ , H-8); 7.46 (1H, dd, $^3J = 8.4$ , $^4J = 1.8$ , H-7); 7.80 (1H, d, $^4J = 1.8$ , H-5)
<b>2b</b>	2217, 1708, 1618, 1581, 1556	1.98-2.15 (2H, m, $\text{CH}_2\text{CH}_2\text{CH}_2$ ); 2.39 (3H, s) and 2.49 (3H, s, 4',6'- $\text{CH}_3$ ); 2.88-3.00 (4H, m, $\text{CH}_2\text{CH}_2\text{CH}_2$ ); 4.72 (2H, s, $\text{CH}_2\text{S}$ ); 6.50 (1H, s, H-3); 7.14 (1H, s, H-5'); 7.25 (1H, s, H-8); 7.80 (1H, s, H-5)
<b>2c</b>	3185, 2216, 1677, 1417	2.40 (3H, s) and 2.50 (3H, s, 4',6'- $\text{CH}_3$ ); 4.70 (2H, s, $\text{CH}_2\text{S}$ ); 6.58 (1H, s, H-3); 7.08 (1H, dd, $^3J = 8.9$ , $^4J = 1.7$ , H-7); 7.16 (1H, s, H-5'); 7.24 (1H, d, $^4J = 1.7$ , H-5); 7.28 (1H, d, $^3J = 8.9$ , H-8); 9.82 (1H, s, OH)
<b>2d</b>	3187, 2217, 1678, 1579, 1416	2.23 (3H, s, 7- $\text{CH}_3$ ); 2.40 (3H, s) and 2.50 (3H, s, 4',6'- $\text{CH}_3$ ); 4.64 (2H, s, $\text{CH}_2\text{S}$ ); 6.50 (1H, s, H-3); 7.15 (1H, s), 7.16 (1H, s) and 7.19 (1H, s, H-5,5')
<b>2e</b>	3193, 2220, 1678, 1579, 1411	2.41 (3H, s) and 2.51 (3H, s, 4',6'- $\text{CH}_3$ ); 4.70 (2H, s, $\text{CH}_2\text{S}$ ); 6.60 (1H, s, H-3); 7.17 (1H, s, H-5'); 7.35 (2H, s, H-5,8'); 7.36-7.47 (3H, m) and 7.62-7.68 (2H, m, H Ph); 10.00 (1H, s, OH)
<b>2f</b>	3245, 2222, 1716, 1599, 1585	2.39 (3H, s) and 2.49 (3H, s, 4',6'- $\text{CH}_3$ ); 4.70 (2H, s, $\text{CH}_2\text{S}$ ); 6.43 (1H, s, H-3); 6.91 (1H, s, H-8); 7.16 (1H, s, H-5'); 8.06 (1H, s, H-5); 11.47 (1H, s, OH)
<b>2g</b>	3238, 2218, 1679, 1605, 1384	1.12 (3H, t, $^3J = 7.5$ , $\text{CH}_2\text{CH}_3$ ); 2.40 (3H, s) and 2.50 (3H, s, 4',6'- $\text{CH}_3$ ); 2.56 (2H, q, $^3J = 7.5$ , $\text{CH}_2\text{CH}_3$ ); 4.72 (2H, s, $\text{CH}_2\text{S}$ ); 6.34 (1H, s, H-3); 6.77 (1H, s, H-8); 7.14 (1H, s, H-5'); 7.61 (1H, s, H-5); 10.61 (1H, s, OH)
<b>2h</b>	3178, 2218, 1678, 1605, 1573	2.16 (3H, s, 8- $\text{CH}_3$ ); 2.39 (3H, s) and 2.49 (3H, s, 4',6'- $\text{CH}_3$ ); 4.67 (2H, s, $\text{CH}_2\text{S}$ ); 6.34 (1H, s, H-3); 6.89 (1H, d, $^3J = 8.8$ , H-6); 7.13 (1H, s, H-5'); 7.63 (1H, d, $^3J = 8.8$ , H-5); 10.44 (1H, s, OH)
<b>3a</b>	3413, 1712, 1699, 1560	2.34 (3H, s, 6- $\text{CH}_3$ ); 2.53 (3H, s) and 2.77 (3H, s, 4',6'- $\text{CH}_3$ ); 5.21 (2H, s, NH <sub>2</sub> ); 6.48 (1H, s, H-3); 7.08 (1H, s, H-5'); 7.38 (1H, d, $^3J = 8.6$ , H-8); 7.47 (1H, dd, $^3J = 8.6$ , $^4J = 1.8$ , H-7); 7.51 (1H, d, $^4J = 1.8$ , H-5)
<b>3b</b>	3411, 1709, 1621, 1548	1.99-2.11 (2H, m, $\text{CH}_2\text{CH}_2\text{CH}_2$ ); 2.52 (3H, s) and 2.77 (3H, s, 4',6'- $\text{CH}_3$ ); 2.82-3.00 (4H, m, $\text{CH}_2\text{CH}_2\text{CH}_2$ ); 5.16 (2H, s, NH <sub>2</sub> ); 6.40 (1H, s, H-3); 7.07 (1H, s, H-5'); 7.34 (1H, s, H-8); 7.50 (1H, s, H-5)
<b>3c</b>	3463, 1673, 1562, 1446, 1230	2.53 (3H, s) and 2.77 (3H, s, 4',6'- $\text{CH}_3$ ); 5.20 (2H, s, NH <sub>2</sub> ); 6.46 (1H, s, H-3); 6.98-7.13 (3H, m, H-5,5'); 7.32 (1H, d, $^3J = 8.4$ , H-8); 9.65 (1H, s, OH)
<b>3d</b>	3442, 1659, 1618, 1444, 1411	2.23 (3H, s, 7- $\text{CH}_3$ ); 2.53 (3H, s) and 2.77 (3H, s, 4',6'- $\text{CH}_3$ ); 5.17 (2H, s, NH <sub>2</sub> ); 6.39 (1H, s, H-3); 7.07 (1H, s, H-5'); 7.12 (1H, s, H-5); 7.24 (1H, s, H-8); 9.60 (1H, s, 6-OH)
<b>3e</b>	3398, 1710, 1562, 1413, 1286	2.53 (3H, s) and 2.79 (3H, s, 4',6'- $\text{CH}_3$ ); 5.24 (2H, s, NH <sub>2</sub> ); 6.49 (1H, s, H-3); 7.08 (1H, s, H-5'); 7.30 (1H, s, H-5); 7.34-7.49 (3H, m, H Ph); 7.62-7.68 (2H, m, H Ph); 7.40 (1H, s, H-8); 9.83 (1H, s, OH)
<b>3f</b>	3465, 1701, 1608, 1448, 1365	2.52 (3H, s) and 2.79 (3H, s, 4',6'- $\text{CH}_3$ ); 5.21 (2H, s, NH <sub>2</sub> ); 6.40 (1H, s, H-3); 6.85 (1H, s, H-8); 7.08 (1H, s, H-5'); 7.35 (1H, s, H-5); 11.52 (1H, s, OH)
<b>3g</b>	3482, 2915, 1697, 1614, 1369	1.10 (3H, t, $^3J = 7.5$ , $\text{CH}_2\text{CH}_3$ ); 2.53 (3H, s) and 2.77 (3H, s, 4',6'- $\text{CH}_3$ ); 2.57 (2H, q, $^3J = 7.5$ , $\text{CH}_2\text{CH}_3$ ); 5.17 (2H, s, NH <sub>2</sub> ); 6.21 (1H, s, H-3); 6.82 (1H, s, H-8); 7.08 (1H, s, H-5'); 7.46 (1H, s, H-5); 10.66 (1H, s, OH)

TABLE 2 (continued)

1	2	3
<b>3h</b>	3411, 1706, 1605, 1562, 1369	2.21 (3H, s, 8-CH <sub>3</sub> ); 2.52 (3H, s) and 2.76 (3H, s, 4',6'-CH <sub>3</sub> ); 5.08 (2H, s, NH <sub>2</sub> ); 6.21 (1H, s, H-3); 6.84 (1H, d, <sup>3</sup> J = 8.8, H-6); 7.06 (1H, s, H-5'); 7.40 (1H, d, <sup>3</sup> J = 8.8, H-5); 10.52 (1H, s, OH)
<b>4a</b>	1708, 1618, 1548, 1421	1.92 (3H, s, 4'-CH <sub>3</sub> ); 1.98-2.10 (2H, m, CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> ); 2.59 (3H, s, 6'-CH <sub>3</sub> ); 2.80-2.99 (4H, m, CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> ); 6.07-6.13 (2H, m, H-2",5"); 6.53 (1H, s, H-3); 6.90-6.96 (2H, m, H-3",4"); 7.22 (1H, s, H-5'); 7.26 (1H, s, H-8); 7.43 (1H, s, H-5)
<b>4b</b>	1685, 1560, 1415, 1211	1.91 (3H, s, 4'-CH <sub>3</sub> ); 2.20 (3H, s, 7-CH <sub>3</sub> ); 2.60 (3H, s, 6'-CH <sub>3</sub> ); 6.12-6.16 (2H, m, H-2",5"); 6.53 (1H, s, H-3); 6.88-6.92 (2H, m, H-3",4"); 6.96 (1H, s, H-5); 7.20 (1H, s, H-5'); 7.25 (1H, s, H-8); 9.60 (1H, s, OH)
<b>4c</b>	3434, 1726, 1600, 1357	1.92 (3H, s, 4'-CH <sub>3</sub> ); 2.60 (3H, s, 6'-CH <sub>3</sub> ); 6.09-6.13 (2H, m, H-2",5"); 6.44 (1H, s, H-3); 6.91 (1H, s, H-8); 6.96-7.00 (2H, m, H-3",4"); 7.23 (1H, s, H-5'); 7.58 (1H, s, H-5); 11.58 (1H, s, OH)
<b>4d</b>	3446, 1728, 1618, 1357, 1272	1.06 (3H, t, <sup>3</sup> J = 7.4, CH <sub>2</sub> CH <sub>3</sub> ); 1.92 (3H, s, 4'-CH <sub>3</sub> ); 2.53 (2H, q, <sup>3</sup> J = 7.4, CH <sub>2</sub> CH <sub>3</sub> ); 2.59 (3H, s, 6'-CH <sub>3</sub> ); 6.09-6.12 (2H, m, H-2",5"); 6.32 (1H, s, H-3); 6.75 (1H, s, H-8); 6.94-6.97 (2H, m, H-3",4"); 7.23 (1H, s, H-5'); 7.31 (1H, s, H-5); 10.71 (1H, s, OH)
<b>6a</b>	2960, 1738, 1589, 1537, 1062	1.38 (9H, s, C(CH <sub>3</sub> ) <sub>3</sub> ); 2.48 (3H, s, 2-CH <sub>3</sub> ); 2.59 (3H, s) and 2.87 (3H, s, 9,11-CH <sub>3</sub> ); 7.27 (1H, s, H-10); 7.36-7.42 (1H, m, H-4); 7.48 (2H, d, <sup>3</sup> J = 8.4, H-3",5'); 7.53-7.59 (1H, m, H-3); 7.64 (2H, d, <sup>3</sup> J = 8.4, H-2",6'); 8.07-8.12 (1H, m, H-1)
<b>6b</b>	3437, 1736, 1540, 1510, 1250	2.45 (3H, s) and 2.69 (3H, s, 9,11-CH <sub>3</sub> ); 3.86 (3H, s, OCH <sub>3</sub> ); 6.98 (2H, d, <sup>3</sup> J = 8.1, H-3",5'); 6.99 (1H, s, H-10); 7.08-7.13 (1H, m, H-3); 7.26-7.30 (1H, m, H-4); 7.56-7.58 (1H, m, H-1); 7.61 (2H, d, <sup>3</sup> J = 8.1, H-2",6'); 10.03 (1H, s, H-2)
<b>6c</b>	3353, 1666, 1556, 1418	1.00 (3H, t, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 2.24 (3H, s) and 2.37 (3H, s, 9,11-CH <sub>3</sub> ); 2.52 (2H, q, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 6.32 (1H, s, H-4); 6.87 (1H, s, H-1); 6.92 (1H, s, H-10); 8.56 (1H, s, H-7); 10.58 (1H, s, OH)
<b>6d</b>	3430, 1733, 1693, 1616, 1504	1.11 (3H, t, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 2.42 (3H, s), 2.49 (3H, s) and 2.59 (3H, s, 7,9,11-CH <sub>3</sub> ); 2.52 (2H, q, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 6.46 (1H, s, H-4); 6.94 (1H, s, H-10); 7.31 (1H, s, H-1); 10.50 (1H, s, OH)
<b>6e</b>	3431, 1720, 1616, 1500, 1249	1.30 (3H, t, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 2.59 (3H, s) and 2.88 (3H, s, 9,11-CH <sub>3</sub> ); 2.68 (2H, q, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 3.87 (3H, s, OCH <sub>3</sub> ); 6.77 (1H, s, H-4); 7.00 (2H, d, <sup>3</sup> J = 8.1, H-3",5'); 7.21 (1H, s, H-10); 7.58 (2H, d, <sup>3</sup> J = 8.1, H-2",6'); 8.03 (1H, s, H-1); 10.56 (1H, s, OH)
<b>6f</b>	3423, 1742, 1612, 1529, 1496, 1257	1.99 (3H, s, 4-CH <sub>3</sub> ); 2.50 (3H, s) and 2.62 (3H, s, 9,11-CH <sub>3</sub> ); 3.73 (3H, s, 3'-OCH <sub>3</sub> ); 3.87 (3H, s, 4'-OCH <sub>3</sub> ); 6.70-6.79 (1H, m, H-2); 6.94-7.02 (2H, m, H-2",5'); 7.11-7.18 (1H, m, H-6'); 7.30 (1H, s, H-10); 7.55-7.57 (1H, m, H-1); 10.58 (1H, s, H-3)
<b>7a</b>	3446, 2964, 1730, 1604, 1560	1.38 (3H, t, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 2.50 (6H, s, N(CH <sub>3</sub> ) <sub>2</sub> ); 2.71 (3H, s) and 3.08 (3H, s, 9,11-CH <sub>3</sub> ); 2.77 (2H, q, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 4.13 (2H, s, CH <sub>2</sub> N); 7.15 (1H, s, H-10); 8.17 (1H, s, H-1); 9.52 (1H, s, H-7)
<b>7b</b>	3437, 2962, 1738, 1605, 1562	1.36 (3H, t, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 2.57-2.87 (9H, m) and 3.06 (3H, s, N(CH <sub>2</sub> ) <sub>2</sub> , CH <sub>2</sub> CH <sub>3</sub> , 9,11-CH <sub>3</sub> ); 3.68-3.97 (4H, m, (CH <sub>2</sub> ) <sub>2</sub> O); 4.16 (2H, s, CH <sub>2</sub> N); 7.13 (1H, s, H-10); 8.08 (1H, s, H-1); 9.43 (1H, s, H-7)
<b>7c</b>	3431, 2927, 1726, 1601, 1558	0.97-1.05 (3H, m, 4'-CH <sub>3</sub> ); 1.39-1.57 (6H, m) and 1.74-1.84 (2H, m, CH <sub>2</sub> CH <sub>3</sub> , 4'-CH, 3",5'-CH <sub>2</sub> ); 2.29-2.45 (2H, m) and 3.10-3.15 (2H, m, N(CH <sub>2</sub> ) <sub>2</sub> ); 2.72 (3H, m) and 3.09 (3H, s, 9,11-CH <sub>3</sub> ); 2.77 (2H, q, <sup>3</sup> J = 7.6, CH <sub>2</sub> CH <sub>3</sub> ); 4.16 (2H, s, CH <sub>2</sub> N); 7.16 (1H, s, H-10); 8.17 (1H, s, H-1); 9.52 (1H, s, H-7)

\*The <sup>1</sup>H NMR spectra of compounds **1f,g**, **2a-h**, **3a-h**, **4a-d**, and **6a-f** were recorded in DMSO-d<sub>6</sub>, and of compounds **7a-c** in CDCl<sub>3</sub>.

**4,6-Dimethyl-2-[(2-oxo-2H-chromen-4-yl)methyl]thio}nicotinonitriles 2a-h (General Method).** A mixture of 3-cyano-2-mercaptop-2,4-dimethylpyridine (1.64 g, 10 mmol) and Et<sub>3</sub>N (1.69 ml, 12 mmol) in warm EtOH (25-30 ml) was added to a solution of 4-chloromethylcoumarin **1a-h** (10 mmol) in the minimum volume of EtOH at 40-50°C. The reaction mixture was stirred at room temperature for 18-24 h, diluted with 5 volumes of water, the precipitated solid was filtered off, and the residue was crystallized from EtOH.

**4-(3-Amino-4,6-dimethylthieno[2,3-*b*]pyridin-2-yl)-2H-chromen-2-ones 3a-h (General Method).** Anhydrous K<sub>2</sub>CO<sub>3</sub> (0.69 g, 5 mmol) was added to a mixture of coumarin **2a-h** (10 mmol) in anhydrous DMF (20 ml) at 60-80°C. The reaction mixture was stirred for 6-8 h at 80-100°C, filtered while hot, the solvent was evaporated, and the residue was crystallized from a 1:1 mixture of DMF-MeOH.

**4-(4,6-Dimethyl-3-(1H-pyrrol-1-yl)thieno[2,3-*b*]pyridin-2-yl)-2H-chromen-2-ones 4a-d (General Method).** A mixture of amine **3b,d,f,g** (2 mmol), 2,5-dimethoxytetrahydrofuran (0.52 ml, 4 mmol), and glacial acetic acid (20 ml) was heated at 90-100°C for 10-15 min, cooled, and the solvent was distilled off in vacuum. The residue was crystallized from MeOH.

**9,11-Dimethyl-6H-chromeno[4,3-*d*]thieno[3,2-*b*:5,4-*b*']dipyridin-6-ones 6a,b,d-f (General Method).** A solution of 4-(3-aminothieno[2,3-*b*]pyridin-2-yl)coumarin **3a,c,g,h** (1.5 mmol) and aldehyde (2.0 mmol) in HCOOH (20 ml) was heated at 40-50°C for 0.5-1 h. Then diacetoxyiodosobenzene (0.8 g, 2.5 mmol) was added to the red solution, and the mixture was stirred at 60-70°C for 2-3 h. The light-yellow colored mixture was diluted with cold water, the precipitated solid was filtered off, dried, and crystallized from DMF (compounds **6a,b,e,f**) or dioxane (compound **6c**).

**2-Ethyl-3-hydroxy-9,11-dimethyl-6H-chromeno[4,3-*d*]thieno[3,2-*b*:5,4-*b*']dipyridin-6-one (6c).** A mixture of compound **3g** (1.1 g, 3 mmol) and triethyl orthoformate (2 ml, 12 mmol) was heated at 110-120°C for 6 h, cooled, diluted with MeOH (5 ml), the precipitated solid was filtered off and crystallized from a 1:2 mixture of DMF-MeOH.

**4-Aminomethyl-2-ethyl-3-hydroxy-9,11-dimethyl-6H-chromeno[4,3-*d*]thieno[3,2-*b*:5,4-*b*']dipyridin-6-ones 7a-c (General Method).** The corresponding aminal (1.2 mmol) was added to a hot solution of compound **6c** (0.38 g, 1.0 mmol) in dioxane (10 ml), the mixture was refluxed for 3-5 h, then cooled. The solvent was evaporated in vacuum, and the residue was crystallized from EtOH.

## REFERENCES

1. J. B. Harborne and H. Baxter, *Handbook of Natural Flavonoids*, Vol. 1-2, John Wiley & Sons, New York (1999).
2. R. D. H. Murray, *Nat. Prod. Rep.*, **12**, 477 (1995).
3. J. B. Harborne (editor), *The Flavonoids: Advances in Research since 1986*, Chapman and Hall, London (1994), p. 239.
4. O. G. Ganina, E. Daras, V. Bourgarel-Rey, V. Peyrot, A. N. Andresyuk, J.-P. Finet, A. Yu. Fedorov, I. P. Beletskaya, and S. Combes, *Bioorg. Med. Chem.*, **16**, 8806 (2008).
5. C. Bailly, C. Bal, P. Barbier, S. Combes, J.-P. Finet, M.-P. Hildebrand, V. Peyrot, and N. Wattez, *J. Med. Chem.*, **46**, 5437 (2003).
6. K. Harada, H. Kubo, Y. Tomigahara, K. Nishioka, J. Takahashi, M. Momose, S. Inoue, and A. Kojima, *Bioorg. Med. Chem. Lett.*, **20**, 272 (2010).
7. I. A. Khan, M. V. Kulkarni, M. Gopal, M. S. Shahabuddin, and C.-M Sun, *Bioorg. Med. Chem. Lett.*, **15**, 3584 (2005).
8. M. M. Garazd, Ya. L. Garazd, and V. P. Khilya, *Khim. Prirod. Soedin.*, 199 (2004).
9. G. M. Boland, D. M. X. Donnelly, J.-P. Finet, and M. D. Rea, *J. Chem. Soc., Perkin Trans. 1*, 2591 (1996).
10. J. Wu and Z. Yang, *J. Org. Chem.*, **66**, 7875 (2001).

11. L. Schio, F. Chartreux, and M. Klich, *Tetrahedron Lett.*, **41**, 1543 (2000).
12. M. S. Frasinyuk, S. V. Gorelov, S. P. Bondarenko, and V. P. Khilya, *Khim. Geterotsikl. Soedin.*, 1568 (2009). [*Chem. Heterocycl. Compd.*, **45**, 1261 (2009).]
13. E. Schlittler and U. Spitaler, *Tetrahedron Lett.*, **19**, 2911 (1978).
14. Y. Fall, L. Santana, M. Teijeira, and E. Uriarte, *Heterocycles*, **41**, 647 (1995).
15. M. S. Frasinyuk, S. P. Bondarenko, and V. P. Khilya, *Khim. Geterotsikl. Soedin.*, 361 (2009). [*Chem. Heterocycl. Compd.*, **45**, 290 (2009)].
16. M. S. Frasinyuk, V. I. Vinogradova, S. P. Bondarenko, and V. P. Khilya, *Khim. Prirod. Soedin.*, 485 (2007).